Evaluation of a pantoprazole and 4-desmethylpantoprazole-sulfate metabolic ratio as a novel CYP2C19 phenotyping method.
Br J Clin PharmacolMay 31, 2026 (epub)
Julian Peter Müller, Vladimir N Belov, Sabrina Yamoune et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated pantoprazole as a novel phenotyping method for CYP2C19 in 20 healthy participants. The study found a very strong correlation (Spearman ρ = 0.84) between the metabolic ratio of 4-desmethylpantoprazole-sulfate/pantoprazole and the established CYP2C19 probe, 5-hydroxyomeprazole/omeprazole, indicating pantoprazole's potential for CYP2C19 phenotyping.
Key findings
- Spearman ρ = 0.84 for AUC 0-8h MR 4-desmethylpantoprazole-sulfate/pantoprazole vs 5-hydroxyomeprazole/omeprazole.
- Single time point pantoprazole MRs between 4 and 8 h showed robust correlations with Spearman ρ ≥ 0.8.
Why it matters
Understanding CYP2C19 activity is crucial for optimizing drug therapy, particularly for medications metabolized by this enzyme. This study suggests that pantoprazole could serve as a reliable phenotyping tool in clinical settings.